Jaguar Health, Inc. (JAGX) shareholders
Close on Nov 16, 2026Market cap $2.02MP/E –Yield –
Ownership
Who owns Jaguar Health's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| John Fife and Fredrick Waid | 1,290,000 | 9.90% | 13G (passive) | Jan 29, 2025 |
| Iliad Management, LLC Joint filing with Iliad Research & Trading, L.P. (9.80%), Fife Trading, Inc. (9.80%) and 1 more | 440,000 | 9.80% | 13G (passive) | Dec 11, 2025 |
| Joshua Mailman | 189,617 | 9.99% | 13G (passive) amendment | Sep 12, 2026 |
| Heights Capital Management, Inc. Joint filing with CVI Investments, Inc. (9.90%) | 103,912 | 9.90% | 13G (passive) | May 20, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lisa A. Conte | See Remarks, Director | 29,258 | 0.57% | Jan 21, 2026 |
| Jonathan S. Wolin | See Remarks | 11,938 | 0.23% | Jan 21, 2026 |
| Steven R. King | See Remarks | 11,885 | 0.23% | Jan 21, 2026 |
| Carol R. Lizak | Chief Financial Officer | 11,912 | 0.23% | Dec 15, 2025 |
| Pravin R. Chaturvedi | Chief Scientific Officer | 11,938 | 0.23% | Dec 15, 2025 |
| John Micek | Director | 7,430 | 0.14% | Mar 12, 2026 |
| Anula Jayasuriya | Director | 5,916 | 0.11% | Dec 15, 2025 |
| James J. Bochnowski | Director | 188,033 | 3.64% | Dec 15, 2025 |
| Jonathan B. Siegel | Director | 7,482 | 0.14% | Dec 15, 2025 |
| Alternative Strategies LLC Lincoln | 10% owner | 600,000 | 11.61% | Aug 29, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John Micek Director | Dec 11, 2025 | Award | +7,377 | – | – | 7,430 |
| Steven R. King See Remarks | Dec 11, 2025 | Award | +11,740 | – | – | 11,885 |
| Jonathan S. Wolin See Remarks | Dec 11, 2025 | Award | +11,740 | – | – | 11,938 |
| Lisa A. Conte See Remarks, Director | Dec 11, 2025 | Award | +28,592 | – | – | 29,258 |
| Carol R. Lizak Chief Financial Officer | Dec 11, 2025 | Award | +11,740 | – | – | 11,911 |
| Jonathan B. Siegel Director | Dec 11, 2025 | Award | +7,377 | – | – | 7,423 |
| James J. Bochnowski Director | Dec 11, 2025 | Award | +6,363 | – | – | 6,415 |
| Anula Jayasuriya Director | Dec 11, 2025 | Award | +5,870 | – | – | 5,916 |
| Pravin R. Chaturvedi Chief Scientific Officer | Dec 11, 2025 | Award | +11,740 | – | – | 11,938 |
| Lisa A. Conte CEO and President, Director | May 17, 2025 | Option exercise | +2 | – | – | 666 |
| Steven R. King See Remarks | May 17, 2025 | Option exercise | +1 | – | – | 145 |
| Steven R. King See Remarks | Oct 8, 2024 | Award | +4,922 | – | – | 4,951 |
| Jonathan S. Wolin See Remarks | Oct 8, 2024 | Award | +4,922 | – | – | 4,955 |
| Lisa A. Conte See Remarks, Director | Oct 8, 2024 | Award | +16,503 | – | – | 16,624 |
| Pravin R. Chaturvedi Chief Scientific Officer | Oct 8, 2024 | Award | +4,922 | – | – | 4,957 |
| Carol R. Lizak Chief Financial Officer | Oct 8, 2024 | Award | +4,280 | – | – | 4,297 |
| Lisa A. Conte CEO and President, Director | May 17, 2024 | Option exercise | +2,695 | – | – | 7,295 |
| Carol R. Lizak Chief Financial Officer | May 17, 2024 | Option exercise | +431 | – | – | 1,042 |
| Pravin R. Chaturvedi Chief Scientific Officer | May 17, 2024 | Option exercise | +871 | – | – | 2,141 |
| Jonathan S. Wolin Chief of Staff, CCO & GC | May 17, 2024 | Option exercise | +871 | – | – | 2,012 |
| Steven R. King See Remarks | May 17, 2024 | Option exercise | +612 | – | – | 1,756 |
| Lisa A. Conte CEO and President, Director | Apr 5, 2024 | Option exercise | +600 | – | – | 4,600 |
| Jonathan S. Wolin Chief of Staff, CCO & GC | Apr 5, 2024 | Option exercise | +89 | – | – | 1,141 |
| Carol R. Lizak Chief Financial Officer | Apr 5, 2024 | Option exercise | +60 | – | – | 611 |
| Steven R. King See Remarks | Apr 5, 2024 | Option exercise | +178 | – | – | 1,144 |
| Pravin R. Chaturvedi Chief Scientific Officer | Apr 5, 2024 | Option exercise | +134 | – | – | 1,270 |
| Steven R. King see remarks | Aug 14, 2023 | Award | +159,168 | – | – | 160,133 |
| Carol R. Lizak Chief Financial Officer | Aug 14, 2023 | Award | +142,088 | – | – | 142,745 |
| Anula Jayasuriya Director | Aug 14, 2023 | Award | +68,568 | – | – | 70,286 |
| Jonathan S. Wolin Chief of Staff, CCO & GC | Aug 14, 2023 | Award | +196,628 | – | – | 197,680 |
| James J. Bochnowski Director | Aug 14, 2023 | Award | +76,613 | – | – | 78,876 |
| Lisa A. Conte CEO and President, Director | Aug 14, 2023 | Award | +383,605 | – | – | 387,605 |
| John Micek Director | Aug 14, 2023 | Award | +68,568 | – | – | 80,701 |
| Pravin R. Chaturvedi Chief Scientific Officer | Aug 14, 2023 | Award | +204,192 | – | – | 205,328 |
| Jonathan B. Siegel Director | Aug 14, 2023 | Award | +68,568 | – | – | 69,874 |
| Anula Jayasuriya Director | Jul 1, 2023 | Award | +1,718 | – | – | 1,718 |
| Carol R. Lizak Chief Financial Officer | May 17, 2023 | Option exercise | +431 | – | – | 657 |
| James J. Bochnowski Director | May 17, 2023 | Option exercise | +1,280 | – | – | 2,263 |
| Steven R. King Chief of Sustainable Supply | May 17, 2023 | Option exercise | +611 | – | – | 965 |
| Jonathan B. Siegel Director | May 17, 2023 | Option exercise | +1,145 | – | – | 1,306 |
| Lisa A. Conte CEO and President, Director | May 17, 2023 | Option exercise | +2,694 | – | – | 4,000 |
| Pravin R. Chaturvedi Chief Scientific Officer | May 17, 2023 | Option exercise | +870 | – | – | 1,136 |
| John Micek Director | May 17, 2023 | Option exercise | +1,145 | – | – | 1,306 |
| Jonathan S. Wolin Chief of Staff, CCO & GC | May 17, 2023 | Option exercise | +871 | – | – | 1,052 |
| Pravin R. Chaturvedi Chief Scientific Officer | Apr 5, 2023 | Option exercise | +133 | – | – | 266 |
| Lisa A. Conte CEO and President, Director | Apr 5, 2023 | Option exercise | +600 | – | – | 1,306 |
| Carol R. Lizak Chief Financial Officer | Apr 5, 2023 | Option exercise | +60 | – | – | 226 |
| Jonathan S. Wolin Chief of Staff, CCO & GC | Apr 5, 2023 | Option exercise | +88 | – | – | 181 |
| Pravin R. Chaturvedi Chief Scientific Officer | Apr 5, 2023 | Option exercise | +44 | – | – | 88 |
| Steven R. King Chief of Sustainable Supply | Apr 5, 2023 | Option exercise | +177 | – | – | 354 |
| Jonathan S. Wolin Chief of Staff, CCO & GC | Dec 31, 2022 | Buy | +317 | $0.03 | $10 | 6,983 |
| Gregory J. Divis Director | May 18, 2022 | Option exercise | +12,133 | – | – | 12,133 |
| John Micek Director | May 18, 2022 | Option exercise | +12,133 | – | – | 12,133 |
| James J. Bochnowski Director | May 18, 2022 | Option exercise | +13,133 | – | – | 73,765 |
| Jonathan B. Siegel Director | May 18, 2022 | Option exercise | +12,133 | – | – | 12,133 |
| Pravin R. Chaturvedi Chief Scientific Officer | Apr 5, 2022 | Option exercise | +10,000 | – | – | 10,000 |
| Carol R. Lizak Chief Financial Officer | Apr 5, 2022 | Option exercise | +4,513 | – | – | 12,481 |
| Lisa A. Conte CEO and President, Director | Apr 5, 2022 | Option exercise | +45,000 | – | – | 53,003 |
| Pravin R. Chaturvedi Chief Scientific Officer | Apr 5, 2022 | Option exercise | +3,333 | – | – | 3,333 |
| Jonathan S. Wolin Chief of Staff, CCO & GC | Apr 5, 2022 | Option exercise | +6,666 | – | – | 6,666 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Jaguar Health's stock actually held short. Settlement fails (shares not delivered on time) peaked at 129,472 shares on Oct 8, 2026 over the last 90 days.
See a number that looks wrong?